Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
07 2월 2008 - 10:00PM
PR Newswire (US)
Conference Call and Webcast to Follow ROCKVILLE, Md., Feb. 7
/PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (NASDAQ:VNDA),
a biopharmaceutical company focused on the development and
commercialization of clinical-stage product candidates for central
nervous system disorders, today announced it will release results
for the quarter and full year ended December 31, 2007, on Thursday,
February 14, 2008, before the market opens. A full text copy of the
release will be disseminated at that time. Mihael H.
Polymeropoulos, M.D., President and Chief Executive Officer, will
host a conference call to discuss the results and other corporate
developments at 10:30 AM ET on Thursday, February 14, 2008. Also
participating on the call will be Steven A. Shallcross, Senior Vice
President and CFO. To participate in the conference call, dial the
appropriate number below shortly before the 10:30 AM start time and
ask for the Vanda Pharmaceuticals conference call hosted by Dr.
Polymeropoulos. The teleconference dial-in numbers are as follows:
Domestic callers 1-866-578-5747 International callers
1-617-213-8054 The conference call will be broadcast simultaneously
and archived on the Company's Web site,
http://www.vandapharma.com/. Investors should go to the Web site at
least 15 minutes early to register, download, and install any
necessary audio software. A replay of the call will be available on
Thursday, February 14, 2008, beginning at 12:30 PM ET and will be
accessible until Thursday, February 21, 2008, at 5:00 PM ET. The
replay call-in number is 1-888-286-8010 for domestic callers and
1-617-801-6888 for international callers. The access number is
16341258. About Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals
Inc. is a biopharmaceutical company focused on the development and
commercialization of clinical-stage product candidates for central
nervous system disorders. The company has three product candidates.
Vanda's lead product candidate, iloperidone, is a compound for the
treatment of schizophrenia and bipolar disorder, for which Vanda
has recently submitted an NDA to the FDA. Vanda's second product
candidate, VEC-162, is a compound for the treatment of sleep and
mood disorders, which is currently in Phase III for sleep
disorders. Vanda's third product candidate, VSF-173, is a compound
for the treatment of excessive sleepiness in Phase II. For more on
Vanda Pharmaceuticals Inc., please visit
http://www.vandapharma.com/. DATASOURCE: Vanda Pharmaceuticals Inc.
CONTACT: Steven A. Shallcross, Senior Vice President & CFO of
Vanda Pharmaceuticals Inc., +1-240-599-4500, Web site:
http://www.vandapharma.com/
Copyright
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024